The NAD+ Economy: Inside the Race to Commercialize Cellular Longevity
John Grey — Healthcare & longevity desk Beta-nicotinamide mononucleotide (β-NMN) is having its moment. Three major trials in 2026 will determine whether this molecule moves from supplement shelf to clinical mainstream. BlackRock's thematic research flags longevity as one of 5 secular trends reshaping healthcare. The addressable market: